Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Monday. The brokerage set a “hold” rating on the stock.

A number of other analysts also recently commented on EKSO. Lake Street Capital assumed coverage on shares of Ekso Bionics in a report on Monday, June 24th. They issued a “buy” rating and a $2.50 price objective for the company. HC Wainwright increased their price target on Ekso Bionics from $9.25 to $10.00 and gave the company a “buy” rating in a report on Tuesday, April 30th.

Ekso Bionics Stock Performance

NASDAQ EKSO opened at $1.33 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.81 and a quick ratio of 2.11. The stock’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $1.51. The company has a market cap of $24.17 million, a PE ratio of -1.37 and a beta of 1.51. Ekso Bionics has a 1-year low of $0.62 and a 1-year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. The firm had revenue of $3.76 million during the quarter, compared to analysts’ expectations of $4.99 million. During the same quarter in the previous year, the business posted ($0.33) EPS. As a group, equities research analysts anticipate that Ekso Bionics will post -0.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

An institutional investor recently bought a new position in Ekso Bionics stock. Kent Lake Capital LLC purchased a new stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned 0.95% of Ekso Bionics as of its most recent filing with the SEC. 6.42% of the stock is owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.